PTN News

  • SCAMP enrolls its first patient May 19, 2014 SCAMP—a randomized, multicenter, open-label Safety study of Clindamycin, Ampicillin, Metronidazole, and Piperacillin-tazobactam in infants with complicated intra-abdominal infections—enrolled its first patient over the weekend. The research team at the University of Florida–Jacksonville Shands Medical Center did the honors, led by site principal investigator Mark Hudak and study coordinator Renee Prince. SCAMP is seeking to determine the ...
  • EnRich Innovative Trial Design Course Being Offered at the Hospital for Sick Children in Toronto May 15, 2014 EnRICH Innovative Trial Design Course
  • SCAMP takes off March 14, 2014 SCAMP is taking off. A randomized, multicenter, open-label safety study of clindamycin, ampicillin, metronidazole, and piperacillin-tazobactam in infants with complicated intra-abdominal infections, SCAMP held its first investigator meeting on 2/28/2014. Twenty-five sites have been selected to date, with an additional 25 sites in the U.S. still to be recruited. To learn more about SCAMP, visit clinicaltrials.gov. ...
  • Methadone study enrolls first patient January 17, 2014 On January 10, 2014, the site team at the Medical University of South Carolina enrolled the first patient into the “Pharmacokinetics of Multiple-dose Methadone in Children” study. Andrew Atz, MD, principal investigator, Hibah Al Nasiri, study coordinator, and Patricia Infinger, research manager, oversee the team at this institution. This multicenter study will determine the pharmacokinetics of ...
  • BPCA study leads to pediatric label change January 17, 2014 A Duke- and Stanford-led study has resulted in key changes being made to the label of a drug used routinely in children to control blood pressure in the perioperative environment. Scott Schulman, MD, of the Duke University Medical Center, in collaboration with co-principal investigator Gregory Hammer, MD, of the Stanford University Medical Center, oversaw this ...
  • One Child’s Appreciation for Research January 14, 2014 The note below from a PTN study participant serves as a reminder of why we do research in children — to provide the best care to kids. We thank the study staff at Seattle Children’s Hospital (Dr. Joseph Flynn, PI, and Megan Kelton-Rehkopf, study coordinator) for sharing this with the PTN community. This note exemplifies ...
  • PTN hydroxyurea trial enrolls its last patient October 28, 2013 On October 23, 2013, the site team at St. Jude Children’s Research Hospital in Memphis, TN, enrolled the last patient into the PTN hydroxyurea study. Overall, 8 sites—Duke University Medical Center, Medical College of Wisconsin, Columbia University Medical Center, Ann & Robert H. Lurie Children’s Hospital of Chicago, Children’s of Alabama, University of Arkansas for ...
  • Acyclovir PK study is complete October 2, 2013 The PTN open-label study to describe the pharmacokinetics (PK) of acyclovir in premature infants has concluded, with results recently published in the Pediatric Infectious Diseases Journal. Acyclovir is a drug used to treat herpes simplex virus (HSV) infections in infants. HSV is a very serious infection in those <6 months of age, often resulting in death ...
  • The PTN lisinopril study completes enrollment September 3, 2013 In spite of the challenges posed by its complex protocol, the “Safety and Pharmacokinetics of Lisinopril in Pediatric Kidney Transplant Recipients” study has completed enrollment, with a total of 26 patients contributing data to this study of lisinopril use for the control of high blood pressure in kids receiving kidney transplants. This accomplishment is due to ...
  • The Pharmacometrics Core of the PTN August 21, 2013 Edmund Capparelli, PharmD, chair of the Pharmacometrics Core of the Pediatric Trials Network, explains the role of pharmacometrics in improving medical treatments for infants and children. http://vimeo.com/46322190